Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Division of Cancer Prevention Staff

Portrait of Nadarajen A. Vydelingum, PhD

Nadarajen A. Vydelingum, PhD

Biologist and Program Director
Cancer Biomarkers Research Group
Division of Cancer Prevention
National Cancer Institute
9609 Medical Center Drive, Room 5E604
Rockville, MD 20850
Phone (240) 276-7127
Fax (240) 276-7846
  • Dr. Nadarajen A Vydelingumis a biologist-program director in DCP/CBRG since 2012. Prior to joining CBRG in 2007, he was an acting-associate director in the DCP Office of Preventive Oncology and later, in 2008, was a member of basic prevention science. From 2002 till 2007, Vydelingum was the deputy director of the NCI CRCHD where he supervised the implementation, coordination, and reporting of NCI health disparities research. Between 1991 and 2002 he worked in CSR with responsibilities for review in bioengineering and physiology.

    His formal scientific education began at the University of London with a PhD in Clinical Biochemistry from St. Mary's Medical School. He continued his work in the USA as a post-doctoral fellow, and soon after as a member of the faculty of Medicine & Pharmacology and director of the GCRC lipid laboratory at the Medical College of Wisconsin. His early research interest in insulin action and fat metabolism related to Type II diabetes and obesity attracted him to MSKCC in 1986 where he led a group in the study of cancer cachexia and the influence of cytokines on lipid/protein stores in cancer patients.

    Dr. Vydelingum is interested in science education and has shared his excitement about science with students in many centers of learning including: the Target MD program at UWM & Marquette University, biochemistry at the NIH FAES, and advances in cell biology at JHU. He is a member of many professional organizations and an active participant as a fellow of: Society of Biology (UK), National Academy of Clinical Biochemists (USA) and Royal Society for Public Health (UK).

  • Screening-detected cancers that are so indolent that they have little or no lethal potential for the person in whom they are detected, also known as cancer overdiagnosis

  • Weighing and reporting the strength of medical evidence

Back to top